Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract

Phase 2

Completed

Conditions: Endometrial Cancer
Sarcoma
Ovarian Cancer
Fallopian Tube Cancer

First Posted Date: 2004-02-09

Last Posted Date: 2016-03-11

Lead Sponsor: NYU Langone Health

Registration Number: NCT00003334

Locations: 🇺🇸
New York Presbyterian Hospital - Cornell Campus, New York, New York, United States
🇺🇸
Albert Einstein Comprehensive Cancer Center, Bronx, New York, United States
🇺🇸
NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York, New York, United States

and more 2 locations

Adjuvant High-Dose, Sequential Chemotherapy in Treating Patients With Resected Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

First Posted Date: 2004-02-06

Last Posted Date: 2009-08-26

Lead Sponsor: Yale University

Target Recruit Count: 89

Registration Number: NCT00002679

Locations: 🇺🇸
Yale Comprehensive Cancer Center, New Haven, Connecticut, United States

Carboplatin and Paclitaxel With or Without ISIS 3521 in Treating Patients With Non-Small Cell Lung Cancer

Phase 3

Completed

Conditions: Lung Cancer

First Posted Date: 2004-02-04

Last Posted Date: 2022-12-05

Lead Sponsor: Ionis Pharmaceuticals, Inc.

Registration Number: NCT00017407

Locations: 🇺🇸
Ireland Cancer Center, Cleveland, Ohio, United States
🇺🇸
ISIS Pharmaceuticals, Inc., Carlsbad, California, United States

Paclitaxel Plus Carboplatin With or Without Topotecan in Treating Patients With Stage IIB, Stage III, or Stage IV Ovarian Epithelial Cancer

Phase 3

Completed

Conditions: Fallopian Tube Cancer
Ovarian Cancer

First Posted Date: 2004-02-03

Last Posted Date: 2015-12-23

Lead Sponsor: AGO Study Group

Registration Number: NCT00006454

Locations: 🇩🇪
Medizinische Klinik I, Dresden, Germany
🇩🇪
Christian-Albrechts University of Kiel, Kiel, Germany
🇩🇪
Zentralkrankenhaus, Bremen, Germany

and more 16 locations

Trastuzumab and Chemotherapy Followed by Surgery and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

First Posted Date: 2004-02-03

Last Posted Date: 2011-03-28

Lead Sponsor: NYU Langone Health

Registration Number: NCT00009997

Locations: 🇺🇸
NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York, New York, United States

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors

Phase 2

Terminated

Conditions: Childhood Germ Cell Tumor
Testicular Germ Cell Tumor
Extragonadal Germ Cell Tumor
Ovarian Cancer

First Posted Date: 2004-01-27

Last Posted Date: 2016-06-23

Lead Sponsor: UNICANCER

Target Recruit Count: 45

Registration Number: NCT00003852

Locations: 🇫🇷
Centre Jean Perrin, Clermont-Ferrand, France
🇫🇷
Centre de Lute Contre le Cancer,Georges-Francois Leclerc, Dijon, France
🇫🇷
Centre Leon Berard, Lyon, France

and more 15 locations

Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Gastric Cancer

Phase 2

Completed

Conditions: Gastric Cancer

Interventions: Drug: cisplatin
Drug: fluorouracil
Drug: leucovorin calcium
Drug: paclitaxel
Procedure: surgery
Radiation: radiation therapy

First Posted Date: 2004-01-23

Last Posted Date: 2023-07-06

Lead Sponsor: ECOG-ACRIN Cancer Research Group

Target Recruit Count: 39

Registration Number: NCT00003298

Locations: 🇺🇸
New England Medical Center Hospital, Boston, Massachusetts, United States
🇺🇸
CCOP - Colorado Cancer Research Program, Inc., Denver, Colorado, United States
🇺🇸
Indiana University Cancer Center, Indianapolis, Indiana, United States

and more 27 locations

Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer
Lung Cancer

First Posted Date: 2004-01-14

Last Posted Date: 2013-04-17

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 29

Registration Number: NCT00021333

Locations: 🇺🇸
St. Francis Medical Center, Trenton, New Jersey, United States
🇺🇸
Southern Chester County Medical Center, West Grove, Pennsylvania, United States
🇺🇸
Kimball Medical Center, Lakewood, New Jersey, United States

and more 15 locations

Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Phase 2

Completed

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Primary Peritoneal Cavity Cancer

First Posted Date: 2004-01-13

Last Posted Date: 2013-08-12

Lead Sponsor: Royal College of Obstetricians and Gynecologists

Target Recruit Count: 150

Registration Number: NCT00075712

Locations: 🇬🇧
Birmingham Women's Hospital, Edgbaston, England, United Kingdom
🇬🇧
Christie Hospital, Manchester, England, United Kingdom
🇬🇧
Derriford Hospital, Plymouth, England, United Kingdom

and more 67 locations

Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer

Phase 3

Completed

Conditions: Neoplasms, Breast

Interventions: Drug: Paclitaxel
Drug: GW572016 (Lapatinib)

First Posted Date: 2004-01-09

Last Posted Date: 2015-05-06

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 580

Registration Number: NCT00075270

Locations: 🇹🇷
GSK Investigational Site, Istanbul, Turkey

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy